Clinical trials
Muscular Atrophy trials in Taiwan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Unknown status | 4 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 6 |
| National Yang Ming Chiao Tung University | 4 |
| Chang Gung Memorial Hospital | 2 |
| National Taiwan University Hospital | 2 |
| Shin Kong Wu Ho-Su Memorial Hospital | 2 |
| Buddhist Tzu Chi General Hospital | 1 |
| Chi-Chang Huang | 1 |
| E-DA Hospital | 1 |
| Far Eastern Memorial Hospital | 1 |
| Orient Europharma Co., Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Muscular Atrophy | 23 |
| Sarcopenia | 6 |
| Muscle Weakness | 3 |
| Muscular Atrophy, Spinal | 3 |
| Muscular Diseases | 3 |
| Bulbo-Spinal Atrophy, X-Linked | 2 |
| Anxiety Disorders | 1 |
| Asthenia | 1 |
| Atrophy | 1 |
| Cachexia | 1 |
Trials
Showing 76 to 23 of 23. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.